Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

Journal of the American Academy of Dermatology

Volumn 43, Issue 3, 2000, Pages 448-458

  Krueger, James G ^a,b,c   Walters, Ian B ^a,b,c   Miyazawa, Megumi ^a,b,c   Gilleaudeau, Patricia ^a,b,c   Hakimi, John ^a,b,c   Light, Susan ^a,b,c   Sherr, Amelia ^a,b,c   Gottlieb, Alice B ^a,b,c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c PhRMA Packaging Working Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; RECEPTOR BLOCKING; T LYMPHOCYTE;

EID: 0033857240     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.106515     Document Type: Article

References (34)

1. Regulation of the human interleukin-2/interleukin-2 receptor system: A role for immunosuppression
2. A humanized antibody that binds to the interleukin 2 receptor
3. A monoclonal antibody, 7G7B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-TAC
4. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
5. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
6. The majority of epidermal T cells in psoriasis vulgaris lesions produce type 1 cytokines IFN-γ, IL-2 and TNF-α, defining TC1 CTL and TH1 effector populations: A type 1 differentiation bias is also measured in circulating T cells in psoriatic patients
7. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry
8. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group
9. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
10. Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor
11. Pathogenic interactions of keratinocytes and T lymphocytes in psoriasis
12. CTLA4lg-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
13. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
14. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection
15. Phase 1 trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB)
16. FK506 in the treatment of inflammatory skin disease: Promises and perspectives
17. Possible metabolic basis for the different immunodeficient states assocated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase
18. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses
19. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4
20. Interferon-γ differentially regulates interleukin-12 and interleukin-10 production in leprosy
21. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-γ in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy
22. IL-10 is a key cytokine in psoriasis
23. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
24. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells
25. Selectins and their ligands: Current concepts and controversies
26. CDS+ T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes
27. Blockade of the interleukin-2 receptor by anti-Tac antibody: Inhibition of human lymphocyte activation
28. Anti-Tac-H, a humanized, antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival
29. Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases
30. Prolongation of primate renal allografts with anti-Tac monoclonal antibody
31. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy
32. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy
33. Synergy with other agents in vitro and in vivo: Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy
34. Consensus workshop on the toxic effects of long-term PUVA therapy